-
1
-
-
73149119363
-
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite
-
Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010; 38(1): 92-99.
-
(2010)
Drug Metab Dispos
, vol.38
, Issue.1
, pp. 92-99
-
-
Kazui, M.1
Nishiya, Y.2
Ishizuka, T.3
-
2
-
-
79960613122
-
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-452C19 (CYP2C19) genotype and clopidogrel therapy
-
Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-452C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011; 90(2): 328-332.
-
(2011)
Clin Pharmacol Ther
, vol.90
, Issue.2
, pp. 328-332
-
-
Scott, S.A.1
Sangkuhl, K.2
Gardner, E.E.3
-
3
-
-
84871919080
-
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response
-
Lewis JP, Horenstein RB, Ryan K, et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics. 2013; 23(1): 1-8.
-
(2013)
Pharmacogenet Genomics
, vol.23
, Issue.1
, pp. 1-8
-
-
Lewis, J.P.1
Horenstein, R.B.2
Ryan, K.3
-
4
-
-
78650517232
-
Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: Randomized, placebo-controlled, crossover comparison studies
-
Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011; 89(1): 65-74.
-
(2011)
Clin Pharmacol Ther
, vol.89
, Issue.1
, pp. 65-74
-
-
Angiolillo, D.J.1
Gibson, C.M.2
Cheng, S.3
-
6
-
-
47649111604
-
The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects
-
Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost. 2008; 6(8): 1439-1441.
-
(2008)
J Thromb Haemost
, vol.6
, Issue.8
, pp. 1439-1441
-
-
Umemura, K.1
Furuta, T.2
Kondo, K.3
-
7
-
-
84863294612
-
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response
-
Kreutz RP, Nystrom P, Kreutz Y, et al. Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. Clin Pharmacol. 2012; 4: 13-20.
-
(2012)
Clin Pharmacol
, vol.4
, pp. 13-20
-
-
Kreutz, R.P.1
Nystrom, P.2
Kreutz, Y.3
-
8
-
-
69249219296
-
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clincal efficacy of clopidogrel
-
Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clincal efficacy of clopidogrel. JAMA. 2009; 302(8): 849-857.
-
(2009)
JAMA
, vol.302
, Issue.8
, pp. 849-857
-
-
Shuldiner, A.R.1
O'Connell, J.R.2
Bliden, K.P.3
-
9
-
-
1642453779
-
Contribution of hepatic cytochrome P450 3 A4 metabolic activity to the phenomenon of clopidogrel resistance
-
Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3 A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004; 109(2): 166-171.
-
(2004)
Circulation
, vol.109
, Issue.2
, pp. 166-171
-
-
Lau, W.C.1
Gurbel, P.A.2
Watkins, P.B.3
-
10
-
-
78951472564
-
The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: Increased platelet inhibition by enhancement of CYP3A4 metabolic activity
-
Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA. The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol. 2011; 57(1): 86-93.
-
(2011)
J Cardiovasc Pharmacol
, vol.57
, Issue.1
, pp. 86-93
-
-
Lau, W.C.1
Welch, T.D.2
Shields, T.3
Rubenfire, M.4
Tantry, U.S.5
Gurbel, P.A.6
-
11
-
-
58749094444
-
Cytochrome p-450 polymorphisms and response to clopidogrel
-
Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360(4): 354-362.
-
(2009)
N Engl J Med
, vol.360
, Issue.4
, pp. 354-362
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
-
12
-
-
84874550138
-
Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function
-
Frelinger AL 3rd, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013; 61(8): 872-879.
-
(2013)
J Am Coll Cardiol
, vol.61
, Issue.8
, pp. 872-879
-
-
Frelinger III, A.L.1
Bhatt, D.L.2
Lee, R.D.3
-
13
-
-
0036890399
-
The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans
-
Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002; 3(6): 561-597.
-
(2002)
Curr Drug Metab
, vol.3
, Issue.6
, pp. 561-597
-
-
Danielson, P.B.1
-
14
-
-
84871450636
-
CYP3A4*22: Promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
-
Elens L, van Gelder T, Hesselink DA, Haufroid V, van Schaik RH. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics. 2013; 14(1): 47-62.
-
(2013)
Pharmacogenomics
, vol.14
, Issue.1
, pp. 47-62
-
-
Elens, L.1
van Gelder, T.2
Hesselink, D.A.3
Haufroid, V.4
van Schaik, R.H.5
-
15
-
-
84861342919
-
PPARA: A novel genetic determinant of CYP3A4 in vitro and in vivo
-
Klein K, Thomas M, Winter S, et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther. 2012; 91(6): 1044-1052.
-
(2012)
Clin Pharmacol Ther
, vol.91
, Issue.6
, pp. 1044-1052
-
-
Klein, K.1
Thomas, M.2
Winter, S.3
-
16
-
-
79960633918
-
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
-
Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011; 11(4): 274-286.
-
(2011)
Pharmacogenomics J
, vol.11
, Issue.4
, pp. 274-286
-
-
Wang, D.1
Guo, Y.2
Wrighton, S.A.3
Cooke, G.E.4
Sadee, W.5
-
17
-
-
0000783041
-
Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method
-
Ozdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000; 10(5): 373-388.
-
(2000)
Pharmacogenetics
, vol.10
, Issue.5
, pp. 373-388
-
-
Ozdemir, V.1
Kalow, W.2
Tang, B.K.3
-
18
-
-
80054924410
-
A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients
-
Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011; 57(11): 1574-1583.
-
(2011)
Clin Chem
, vol.57
, Issue.11
, pp. 1574-1583
-
-
Elens, L.1
Bouamar, R.2
Hesselink, D.A.3
-
19
-
-
81055140354
-
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study
-
Elens L, Becker ML, Haufroid V, et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics. 2011; 21(12): 861-866.
-
(2011)
Pharmacogenet Genomics
, vol.21
, Issue.12
, pp. 861-866
-
-
Elens, L.1
Becker, M.L.2
Haufroid, V.3
-
20
-
-
84859900517
-
The new CYP3A4 intron 6 C. T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients
-
Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. The new CYP3A4 intron 6 C. T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics. 2012; 22(5): 373-380.
-
(2012)
Pharmacogenet Genomics
, vol.22
, Issue.5
, pp. 373-380
-
-
Elens, L.1
Bouamar, R.2
Hesselink, D.A.3
Haufroid, V.4
van Gelder, T.5
van Schaik, R.H.6
-
21
-
-
38349168418
-
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry
-
Jakubowski JA, Payne CD, Li YG, et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost. 2008; 99(1): 215-222.
-
(2008)
Thromb Haemost
, vol.99
, Issue.1
, pp. 215-222
-
-
Jakubowski, J.A.1
Payne, C.D.2
Li, Y.G.3
-
22
-
-
73949112820
-
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study
-
Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009; 120(25): 2577-2585.
-
(2009)
Circulation
, vol.120
, Issue.25
, pp. 2577-2585
-
-
Gurbel, P.A.1
Bliden, K.P.2
Butler, K.3
-
23
-
-
35848934339
-
Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists
-
Kreutz RP, Tantry US, Bliden KP, Gurbel PA. Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists. Blood Coagul Fibrinolysis. 2007; 18(8): 713-718.
-
(2007)
Blood Coagul Fibrinolysis
, vol.18
, Issue.8
, pp. 713-718
-
-
Kreutz, R.P.1
Tantry, U.S.2
Bliden, K.P.3
Gurbel, P.A.4
-
24
-
-
79953114829
-
Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity
-
Kreutz RP, Alloosh M, Mansour K, et al. Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity. Diabetes Metab Syndr Obes. 2011; 4: 99-105.
-
(2011)
Diabetes Metab Syndr Obes
, vol.4
, pp. 99-105
-
-
Kreutz, R.P.1
Alloosh, M.2
Mansour, K.3
-
25
-
-
84864409943
-
Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response
-
Kreutz RP, Breall JA, Kreutz Y, et al. Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response. Thromb Res. 2012; 130(2): 198-202.
-
(2012)
Thromb Res
, vol.130
, Issue.2
, pp. 198-202
-
-
Kreutz, R.P.1
Breall, J.A.2
Kreutz, Y.3
-
26
-
-
27444434164
-
Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation
-
Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005; 46(9): 1705-1709.
-
(2005)
J Am Coll Cardiol
, vol.46
, Issue.9
, pp. 1705-1709
-
-
Tantry, U.S.1
Bliden, K.P.2
Gurbel, P.A.3
-
27
-
-
84877780144
-
The CYP3A4 intron 6 C. T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes
-
Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H. The CYP3A4 intron 6 C. T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci. 2013; 38(3): 349-354.
-
(2013)
J Toxicol Sci
, vol.38
, Issue.3
, pp. 349-354
-
-
Okubo, M.1
Murayama, N.2
Shimizu, M.3
Shimada, T.4
Guengerich, F.P.5
Yamazaki, H.6
-
28
-
-
57149084688
-
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects
-
Farid NA, Small DS, Payne CD, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy. 2008; 28(12): 1483-1494.
-
(2008)
Pharmacotherapy
, vol.28
, Issue.12
, pp. 1483-1494
-
-
Farid, N.A.1
Small, D.S.2
Payne, C.D.3
-
29
-
-
58149466606
-
PPARs mediate lipid signaling in inflammation and cancer
-
Michalik L, Wahli W. PPARs mediate lipid signaling in inflammation and cancer. PPAR Res. 2008; 2008: 134059.
-
(2008)
PPAR Res
, vol.2008
, pp. 134059
-
-
Michalik, L.1
Wahli, W.2
-
30
-
-
69449086702
-
Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human
-
Rakhshandehroo M, Hooiveld G, Müller M, Kersten S. Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One. 2009; 4(8): e6796.
-
(2009)
PLoS One
, vol.4
, Issue.8
-
-
Rakhshandehroo, M.1
Hooiveld, G.2
Müller, M.3
Kersten, S.4
-
31
-
-
41149153511
-
The tangle of nuclear receptors that controls xenobiotic metabolism and transport: Crosstalk and consequences
-
Pascussi JM, Gerbal-Chaloin S, Duret C, Daujat-Chavanieu M, Vilarem MJ, Maurel P. The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol. 2008; 48: 1-32.
-
(2008)
Annu Rev Pharmacol Toxicol
, vol.48
, pp. 1-32
-
-
Pascussi, J.M.1
Gerbal-Chaloin, S.2
Duret, C.3
Daujat-Chavanieu, M.4
Vilarem, M.J.5
Maurel, P.6
-
32
-
-
80053509605
-
Pathway-targeted pharmacogenomics of CYP1 A2 in human liver
-
Klein K, Winter S, Turpeinen M, Schwab M, Zanger UM. Pathway-targeted pharmacogenomics of CYP1 A2 in human liver. Front Pharmacol. 2010; 1: 129.
-
(2010)
Front Pharmacol
, vol.1
, pp. 129
-
-
Klein, K.1
Winter, S.2
Turpeinen, M.3
Schwab, M.4
Zanger, U.M.5
-
33
-
-
82955189275
-
A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation
-
Park DW, Lee SW, Yun SC, et al. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation. J Am Coll Cardiol. 2011; 58(25): 2630-2639.
-
(2011)
J Am Coll Cardiol
, vol.58
, Issue.25
, pp. 2630-2639
-
-
Park, D.W.1
Lee, S.W.2
Yun, S.C.3
|